ArticleiScience2026
The basic domain of Suv39h2 buffers mitoxantrone-induced heterochromatin destabilization.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Suv39h1 and Suv39h2 are core components of mouse heterochromatin, where they direct H3K9me3, which is recognized by HP1. In mouse embryonic fibroblasts, heterochromatin retention modes of Suv39h enzymes differ from HP1 and are not sensitive to compounds that impair liquid-liquid phase separation. Suv39h2 contains an N-terminal basic domain that is also present in around 23% of annotated Suv39h orthologs. The Suv39h2 basic domain provides resistance to chromatin-destabilizing agents, such as mitoxantrone and curaxin, and protects H3K9me3 heterochromatin from unfolding or chemically induced histone eviction. This protective function of the basic domain can be transferred to Suv39h1 as an N-terminal fusion. Together, these findings identify the Suv39h2 basic domain as a structural component of heterochromatin and suggest that basic domain extensions help to buffer heterochromatin destabilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.